| Not Yet Recruiting | Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-O NCT06630273 | Canadian Cancer Trials Group | — |
| Not Yet Recruiting | Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanc NCT07489066 | Pfizer | Phase 2 |
| Recruiting | Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstru NCT07257094 | Hôpital NOVO | — |
| Not Yet Recruiting | MRinRT: Swansea University and SWWCC Collaboration Study. NCT07365124 | Swansea Bay University Health Board | — |
| Not Yet Recruiting | The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Mult NCT07180459 | Xuhua Duan | — |
| Recruiting | Safety and Efficacy of Pucotenlimab in pLECC NCT06969534 | Sun Yat-sen University | Phase 2 |
| Recruiting | Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer NCT06445114 | Zachary Zumsteg | Phase 2 |
| Recruiting | A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezo NCT07246668 | Yonsei University | Phase 2 |
| Recruiting | A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patie NCT07252323 | Yonsei University | N/A |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Active Not Recruiting | Evaluation of 'WAYMED Endo CL CS' for Automated Detection and Diagnosis of Colorectal Adenoma and Non-Adenoma NCT07470827 | WAYCEN Inc | — |
| Recruiting | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma NCT06676527 | Jinling Hospital, China | — |
| Active Not Recruiting | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanc NCT06317311 | GlaxoSmithKline | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC NCT06364046 | The Central Hospital of Lishui City | N/A |
| Recruiting | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cispla NCT05910177 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) NCT06358222 | Shanghai Chest Hospital | — |
| Recruiting | Anatomical-Clinical Base of Adenocarcinoma Pancreatic NCT06128343 | University Hospital, Toulouse | — |
| Recruiting | Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases NCT06545630 | West China Hospital | Phase 1 |
| Unknown | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer NCT06134193 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Not Yet Recruiting | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tum NCT06112041 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients NCT06013111 | China Medical University, China | Phase 1 |
| Recruiting | Impact of Peri-Operative Hyponatremia on Postoperative Outcomes in Major HPB Surgeries for Cancers NCT06475911 | Institute of Liver and Biliary Sciences, India | — |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W NCT06022757 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma NCT05559879 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Unknown | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma NCT05913661 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Unknown | Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery NCT04962958 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors NCT05961111 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Completed | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA NCT05848947 | Sirtex Medical | Phase 4 |
| Recruiting | Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cance NCT05065736 | Roberto Vargas | EARLY_Phase 1 |
| Unknown | A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (V NCT05708950 | Kineta Inc. | Phase 1 / Phase 2 |
| Unknown | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors NCT05860374 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Unknown | Home Management of Simple Hydromorphone PCA Pump Mode NCT05744089 | The First Affiliated Hospital of Xinxiang Medical College | N/A |
| Recruiting | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Part NCT05592626 | Marengo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study) NCT05917106 | Jinling Hospital, China | — |
| Recruiting | A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcino NCT05917158 | Jinling Hospital, China | Phase 2 |
| Recruiting | Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With R NCT05283226 | NATCO Pharma Ltd. | Phase 2 |
| Completed | Short-term Psychodynamic Psychotherapy in Serious Physical Illness NCT05520281 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Active Not Recruiting | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lu NCT05261399 | AstraZeneca | Phase 3 |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Recruiting | Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients NCT06456411 | Roswell Park Cancer Institute | N/A |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esopha NCT05494060 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873 | Blueprint Medicines Corporation | Phase 1 |
| Unknown | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors NCT05235607 | Sichuan University | Phase 1 |
| Completed | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma NCT05188729 | Verrica Pharmaceuticals Inc. | Phase 2 |
| Terminated | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408 | Blueprint Medicines Corporation | Phase 1 |
| Unknown | Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) NCT05094882 | Fudan University | — |
| Recruiting | Registry Platform Ovarian and Endometrial Cancer NCT05129969 | iOMEDICO AG | — |
| Completed | App Teaches Doctors to Diagnose Skin Cancer NCT05661370 | Herlev Hospital | N/A |
| Completed | Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings NCT04931251 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registrati NCT05463757 | Maastricht University Medical Center | — |
| Unknown | ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 NCT05115500 | Second Affiliated Hospital of Soochow University | Phase 2 |
| Unknown | The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer. NCT05752357 | Chang Gung Memorial Hospital | — |
| Completed | Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer NCT05023928 | Sichuan University | Phase 1 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Recruiting | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 | Simcha IL-18, Inc. | Phase 1 / Phase 2 |
| Terminated | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780 | Blueprint Medicines Corporation | Phase 1 |
| Completed | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients NCT05375136 | Eisai Korea Inc. | — |
| Active Not Recruiting | Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients NCT04641819 | ShuGuang Hospital | Phase 4 |
| Recruiting | Propofol vs Sevo for Paediatric Tumor Surgery NCT04475705 | Hong Kong Children's Hospital | Phase 4 |
| Unknown | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446 | Blueprint Medicines Corporation | — |
| Unknown | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study NCT04401059 | Tian Xie | Phase 4 |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Completed | Existential Distress in Patients with Advanced Cancer and Their Caregivers NCT04600206 | Universitätsklinikum Hamburg-Eppendorf | — |
| Completed | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer NCT04362072 | Pfizer | Phase 4 |
| Completed | Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma NCT05593744 | Qilu Hospital of Shandong University | — |
| Terminated | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Completed | A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of C NCT04419623 | Telios Pharma, Inc. | Phase 1 |
| Completed | Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma NCT04429490 | CHU de Reims | N/A |
| Completed | Smartphone App for Cancer Medication Adherence NCT05225090 | Columbia University | N/A |
| Withdrawn | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease NCT01125449 | Situs Cancer Research Center | Phase 2 |
| Unknown | A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carbo NCT03952403 | Shanghai Henlius Biotech | Phase 3 |
| Withdrawn | Efficacy and Safety of UGN-101 in Recurrent Patients NCT04006691 | UroGen Pharma Ltd. | Phase 3 |
| Unknown | Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) NCT04124731 | Shanghai Chest Hospital | Phase 2 |
| Completed | Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. NCT04033991 | Pfizer | — |
| Active Not Recruiting | Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer NCT03857620 | Alliance for Clinical Trials in Oncology | N/A |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Completed | A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma NCT04008082 | Eisai Co., Ltd. | — |
| Unknown | Multiplex Analysis of Circulating Tumor DNA NCT03301961 | Peking University People's Hospital | — |
| Unknown | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions NCT03549273 | Catalysis SL | Phase 2 |
| Recruiting | Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck NCT03708224 | Alain Algazi | Phase 2 |
| Active Not Recruiting | Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma NCT04124198 | Christian von Buchwald | N/A |
| Completed | Detecting Lung Cancer Based on Exhaled Breath NCT04419207 | Peking University People's Hospital | — |
| Withdrawn | Sym004 Versus TAS-102 in Patients With mCRC NCT03717038 | Symphogen A/S | Phase 3 |
| Active Not Recruiting | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib NCT03778229 | AstraZeneca | Phase 2 |
| Unknown | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC NCT03780283 | First Hospital of Shijiazhuang City | Phase 2 |
| Unknown | Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin NCT03699332 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Unknown | Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients NCT02696525 | Peking University People's Hospital | — |
| Terminated | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC NCT03549338 | Symphogen A/S | Phase 2 |
| Unknown | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NCT03765775 | First Hospital of Shijiazhuang City | Phase 2 |
| Unknown | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients NCT03664843 | First Hospital of Shijiazhuang City | — |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer NCT03562897 | Catalysis SL | Phase 2 |
| Unknown | Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer P NCT03634826 | Peking University People's Hospital | — |
| Withdrawn | Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cance NCT03240393 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cel NCT03546166 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Completed | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. NCT03611556 | MedImmune LLC | Phase 1 / Phase 2 |
| Completed | Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO NCT03515174 | National Cancer Centre, Singapore | N/A |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Unknown | Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell NCT03288298 | Cairo University | EARLY_Phase 1 |
| Completed | Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing NCT03320044 | Peking University People's Hospital | — |
| Recruiting | Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients NCT03331601 | Universitair Ziekenhuis Brussel | Phase 2 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Savolitinib vs. Sunitinib in MET-driven PRCC. NCT03091192 | AstraZeneca | Phase 3 |
| Active Not Recruiting | Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling NCT03208374 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer NCT02898116 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Completed | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Ceramide NanoLiposome in Patients With Advanced Solid Tumors NCT02834611 | Keystone Nano, Inc | Phase 1 |
| Completed | Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients NCT02965391 | Peking University People's Hospital | — |
| Unknown | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours NCT02977364 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study NCT02907606 | Peking University People's Hospital | — |
| Completed | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumo NCT02867007 | Kyowa Kirin, Inc. | Phase 1 |
| Withdrawn | Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection NCT02851693 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Completed | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced NCT02737501 | Ariad Pharmaceuticals | Phase 3 |
| Completed | What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors NCT02840604 | Centre Georges Francois Leclerc | — |
| Completed | Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients NCT02703298 | TaiRx, Inc. | Phase 1 |
| Completed | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors NCT02705105 | Kyowa Kirin, Inc. | Phase 1 / Phase 2 |
| Unknown | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients NCT02526953 | Blokhin's Russian Cancer Research Center | Phase 3 |
| Unknown | Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection NCT02433574 | Juravinski Cancer Center | N/A |
| Completed | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC NCT02592577 | Adaptimmune | Phase 1 |
| Completed | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma NCT02539537 | UNICANCER | Phase 3 |
| Unknown | Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With L NCT02567734 | Yueyong Xiao | N/A |
| Unknown | Radiofrequency Ablation of Malignant Pulmonary Nodules NCT02629978 | Chinese PLA General Hospital | N/A |
| Completed | A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer NCT02507544 | TaiRx, Inc. | Phase 1 |
| Terminated | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer NCT02473094 | University of Campinas, Brazil | Phase 2 |
| Unknown | Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA NCT02833467 | Peking University People's Hospital | — |
| Recruiting | Beyond TME Origins NCT02292641 | Imperial College London | N/A |
| Completed | Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Eld NCT02151149 | Celgene | Phase 4 |
| Withdrawn | EBUS-TBNA Versus EBUS-TBNB NCT01467635 | Royal Brompton & Harefield NHS Foundation Trust | N/A |
| Completed | Registry for Proton Beam Radiation Therapy NCT02040467 | Washington University School of Medicine | — |
| Withdrawn | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab NCT01345084 | Eurofarma Laboratorios S.A. | Phase 3 |
| Unknown | Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy NCT02303353 | SPGO Research Mannheim GmbH | — |
| Completed | A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer NCT01942200 | Onkovis GmbH | — |
| Completed | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative NCT01916135 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous In NCT01995942 | Royal Marsden NHS Foundation Trust | — |
| Completed | A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer NCT01840280 | Onkovis GmbH | — |
| Completed | Identification of a Plasma Proteomic Signature for Lung Cancer NCT01752101 | Integrated Diagnostics | — |
| Completed | Early Diagnosis of Pulmonary Nodules NCT01752114 | Integrated Diagnostics | — |
| Completed | A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer NCT01668108 | Onkovis GmbH | — |
| Completed | Systems Intervention to Promote Colorectal Cancer (CRC) Screening NCT01299493 | Washington University School of Medicine | N/A |
| Unknown | Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate He NCT01556815 | Shandong Cancer Hospital and Institute | Phase 2 |
| Completed | A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer NCT01614002 | Onkovis GmbH | — |
| Completed | Continuous Infusion of rhIL-15 for Adults With Advanced Cancer NCT01572493 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors NCT01479023 | Washington University School of Medicine | Phase 1 |
| Completed | Assessment of Patient Experience During Treatment for Cancer NCT01553825 | Stanford University | — |
| Unknown | S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC) NCT01533324 | Second Military Medical University | Phase 2 |
| Completed | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. NCT01398306 | University Medical Center Groningen | — |
| Completed | Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma NCT01339975 | University Hospital, Bordeaux | — |
| Active Not Recruiting | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal C NCT01061515 | Washington University School of Medicine | Phase 1 |
| Withdrawn | Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of NCT01301612 | Eurofarma Laboratorios S.A. | Phase 2 |
| Unknown | Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract NCT01361100 | Centre Leon Berard | N/A |
| Completed | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer NCT01253681 | Amgen | Phase 1 |
| Unknown | Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC NCT01214343 | Ministry of Health, Labour and Welfare, Japan | Phase 3 |
| Completed | Study of MOC31-PE in Antigen Positive Carcinomas NCT01061645 | Oslo University Hospital | Phase 1 |
| Completed | A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery NCT01223209 | Lytix Biopharma AS | Phase 1 |
| Completed | Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung NCT01109524 | Eli Lilly and Company | Phase 2 |
| Terminated | Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepat NCT01097083 | National University Hospital, Singapore | Phase 2 |
| Completed | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Trea NCT01035229 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) NCT01009593 | Abbott | Phase 3 |
| Completed | Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions. NCT01043523 | Bayer | — |
| Unknown | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks NCT01037049 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Terminated | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ova NCT01016054 | Astellas Pharma Inc | Phase 1 |
| Completed | Molecular Biology of Anal Cancer in HIV-Positive Patients NCT00952874 | University Hospital, Geneva | — |
| Unknown | Paclitaxel/Carboplatin With or Without Cetuximab in CUP NCT00894569 | Heidelberg University | Phase 2 |
| Completed | RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe NCT00688753 | Novartis Pharmaceuticals | Phase 2 |
| Completed | CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial NCT00847912 | VA Office of Research and Development | Phase 4 |
| Completed | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe NCT00688623 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma NCT01149161 | Samsung Medical Center | Phase 2 / Phase 3 |
| Completed | A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cel NCT00863746 | Bayer | Phase 3 |
| Completed | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prosta NCT00838201 | Amgen | Phase 3 |
| Completed | A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer NCT00781911 | Eli Lilly and Company | Phase 2 |
| Completed | Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-000 NCT00599755 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial O NCT00770536 | Amgen | Phase 1 |
| Completed | CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites NCT00822809 | Neovii Biotech | Phase 3 |
| Completed | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Tr NCT00719264 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjec NCT00752570 | Amgen | Phase 2 |
| Completed | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer NCT00816764 | Astellas Pharma Inc | Phase 1 |
| Completed | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site NCT00737243 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage NCT00742222 | Xoft, Inc. | Phase 4 |
| Completed | Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients NCT00728130 | Southern Illinois University | Phase 1 |
| Terminated | A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer NCT00672009 | Cedars-Sinai Medical Center | Phase 2 |
| Terminated | Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer NCT00804830 | Region Skane | Phase 2 |
| Completed | Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and NCT01070537 | Centre Leon Berard | Phase 2 |
| Completed | A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics NCT00613691 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Completed | Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors NCT00879684 | Pfizer | Phase 1 |
| Completed | A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Pa NCT00613652 | AstraZeneca | Phase 1 |
| Unknown | Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy NCT00396617 | University Hospital, Strasbourg, France | Phase 1 |
| Completed | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma NCT00565448 | Sanofi | Phase 2 |
| Completed | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) NCT00446446 | Amgen | Phase 2 |
| Completed | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastati NCT00532155 | Sanofi | Phase 3 |
| Terminated | A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer NCT00557596 | Aegera Therapeutics | Phase 1 / Phase 2 |
| Unknown | Low Rectal Cancer Study (MERCURY II) NCT02005965 | Royal Marsden NHS Foundation Trust | — |
| Withdrawn | A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab NCT00477425 | Genentech, Inc. | — |
| Completed | Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma NCT00466583 | Enzon Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors NCT00879554 | Pfizer | Phase 1 |
| Completed | Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors NCT00447005 | Pfizer | Phase 1 |
| Completed | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer NCT00420381 | Eli Lilly and Company | Phase 2 |
| Completed | Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases NCT00327652 | Anza Therapeutics, Inc. | Phase 1 |
| Completed | The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer NCT00243347 | AstraZeneca | Phase 1 |
| Completed | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer NCT00152477 | UCB Pharma | Phase 2 |
| Completed | ZD6474(Vandetanib) + Alimta Combo Study NCT00506051 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Molecular Profiling in Lung Cancer Patients NCT00191308 | Eli Lilly and Company | Phase 2 |
| Completed | Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tum NCT00731861 | Indiana University School of Medicine | Phase 1 |
| Completed | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer NCT01215500 | University of Chicago | Phase 1 |
| Completed | ARQ 501 in Combination With Docetaxel in Patients With Cancer NCT00099190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 1 |
| Completed | Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer NCT00097903 | BioNumerik Pharmaceuticals, Inc. | Phase 1 |
| Completed | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis NCT00216372 | Ipsen | Phase 3 |
| Completed | Colonoscope Passive Bending Function NCT00518349 | Norwegian Department of Health and Social Affairs | N/A |
| Unknown | Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary NCT00126269 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Completed | Automated Telephone Monitoring for Symptom Management NCT00799084 | Michigan State University | Phase 2 |
| Completed | Pain and Fatigue Study NCT00006253 | Michigan State University | N/A |
| Completed | Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer NCT00364455 | Janssen-Ortho Inc., Canada | Phase 3 |
| Completed | Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) NCT00941863 | Bayer | Phase 1 |
| Terminated | Darbepoetin Alfa and Anemia of Cancer NCT00989092 | Amgen | Phase 2 |
| Completed | Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma NCT00111774 | Amgen | Phase 2 |
| Enrolling By Invitation | Collection of Blood and Urine From Patients Undergoing Radiation Therapy NCT00027326 | National Cancer Institute (NCI) | — |
| Completed | Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases NCT00129051 | Alberta Health services | Phase 1 |
| Completed | Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) NCT00183742 | University of Southern California | Phase 1 |
| Completed | Iressa Expanded Access Program (EAP) NCT00034879 | AstraZeneca | Phase 3 |
| Completed | Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer NCT00301548 | European Institute of Oncology | Phase 2 |
| Completed | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative I NCT00001569 | National Cancer Institute (NCI) | Phase 1 |
| No Longer Available | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer NCT02784158 | Ariad Pharmaceuticals | — |
| No Longer Available | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC NCT06841874 | Nuvation Bio Inc. | — |